CNSide Diagnostics, LLC Partners with UnitedHealthcare to Provide CNSide® CSF Assay to Over 51 Million Americans

CNSide Diagnostics signs agreement with UnitedHealthcare to provide CNSide® test for over 51 million in the U.S.

Quiver AI Summary

CNSide Diagnostics, a subsidiary of Plus Therapeutics, has entered into a national agreement with UnitedHealthcare, effective September 15, 2025, which will provide the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration test to over 51 million individuals across the U.S. The CNSide® CSF Assay enables efficient diagnosis and treatment monitoring for patients with leptomeningeal metastases and has demonstrated superior clinical utility compared to standard care, supported by extensive research and over 11,000 tests conducted since 2020. This test, which shows high sensitivity and specificity, is exclusively available through CNSide Diagnostics for healthcare professionals. Plus Therapeutics focuses on developing targeted therapies for challenging central nervous system cancers, aiming to enhance clinical outcomes through innovative drug delivery methods.

Potential Positives

CNSide Diagnostics has secured a national agreement with UnitedHealthcare, significantly expanding its market reach to over 51 million people in the U.S.
The CNSide® CSF Assay is backed by strong clinical data, with demonstrated high sensitivity (92%) and specificity (95%), influencing treatment decisions in 90% of cases.
This agreement positions CNSide Diagnostics as a crucial player in the management of leptomeningeal metastases, potentially leading to increased adoption and reimbursement for its diagnostic services.

Potential Negatives

The press release relies heavily on forward-looking statements, which could raise concerns about the company's actual future performance relative to expectations.
Despite the significant partnership with UnitedHealthcare, it is unclear how this agreement will directly impact revenue and profitability, creating uncertainty for stakeholders.
The exclusive offering of the CNSide test through CNSide Diagnostics may limit broader market penetration and collaborations, potentially hindering growth opportunities.

FAQ

What is the CNSide® CSF Assay Platform?

The CNSide® CSF Assay Platform is a laboratory-developed test for quantifying tumor cells in cerebrospinal fluid from patients with leptomeningeal metastases.

Who are the partners involved in this agreement?

The agreement involves CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, and UnitedHealthcare Insurance Company.

How does the CNSide® test impact treatment decisions?

The CNSide® test influences treatment decisions in 90% of cases, improving patient management for those with leptomeningeal metastases.

Where is the CNSide® test available?

The CNSide® test is exclusively available through CNSide Diagnostics, LLC, provided to healthcare professionals across the U.S.

What is Plus Therapeutics, Inc. focused on?

Plus Therapeutics, Inc. develops targeted radiotherapeutics for challenging central nervous system cancers to enhance clinical outcomes.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$PSTV Insider Trading Activity

$PSTV insiders have traded $PSTV stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $PSTV stock by insiders over the last 6 months:

ROBERT P LENK purchased 110,000 shares for an estimated $53,779

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$PSTV Hedge Fund Activity

We have seen 11 institutional investors add shares of $PSTV stock to their portfolio, and 11 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AIGH CAPITAL MANAGEMENT LLC removed 560,905 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $532,915
JANE STREET GROUP, LLC added 117,454 shares (+inf%) to their portfolio in Q2 2025, for an estimated $40,850
HRT FINANCIAL LP removed 102,065 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $35,498
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 80,505 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $27,999
UBS GROUP AG added 54,201 shares (+162.1%) to their portfolio in Q2 2025, for an estimated $18,851
VIRTU FINANCIAL LLC removed 40,030 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $13,922
GOLDMAN SACHS GROUP INC added 26,753 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,304

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$PSTV Analyst Ratings

Wall Street analysts have issued reports on $PSTV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

D. Boral Capital issued a "Buy" rating on 09/22/2025
Maxim Group issued a "Buy" rating on 08/18/2025
HC Wainwright & Co. issued a "Buy" rating on 06/27/2025
Ascendiant Capital issued a "Buy" rating on 06/05/2025

To track analyst ratings and price targets for $PSTV, check out Quiver Quantitative's $PSTV forecast page.

$PSTV Price Targets

Multiple analysts have issued price targets for $PSTV recently. We have seen 4 analysts offer price targets for $PSTV in the last 6 months, with a median target of $4.0.

Here are some recent targets:

Jason Kolbert from D. Boral Capital set a target price of $5.0 on 09/22/2025
Jason McCarthy from Maxim Group set a target price of $3.0 on 08/18/2025
Sean Lee from HC Wainwright & Co. set a target price of $3.0 on 06/27/2025
Edward Woo from Ascendiant Capital set a target price of $20.5 on 06/05/2025

Full Release

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it has signed a national agreement with UnitedHealthcare Insurance Company (NYSE: UNH ), effective September 15, 2025, covering over 51 million people throughout the United States, to provide the CNSide ^® Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test (LDT).

The CNSide ^® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide ^® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.

More than 11,000 CNSide ^® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.

This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.

About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide ^® , designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide ^® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/ .

About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com .

About UnitedHealthcare Group
UnitedHealth Group (NYSE: UNH ) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com

Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Investor Contact
CORE IR
[email protected]